eFFECTOR Therapeutics, Inc. announced the initiation of dosing in the Phase IIa expansion portion of an ongoing Phase I/II trial of zotatifin in solid tumors. eFFECTOR expects to initiate multiple indication-specific expansion cohorts in ER+ breast cancer and KRAS-mutant non-small cell lung cancer.
[eFFECTOR Therapeutics, Inc.]
Sorry, but the selected Zotpress account can't be found.
